ARTICLE | Clinical News
MK-8408: Phase I data
April 25, 2016 7:00 AM UTC
Top-line data from 9 patients with chronic HCV infection in the double-blind Phase I MK-8408-003 trial showed that once-daily 60 mg oral MK-8408 for 5 days led to mean maximal HCV viral load reduction...